Haseeb Chaudhary1, Nidrit Bohra1, Khezar Syed1, Anthony Donato1, M Hassan Murad2, Paras Karmacharya3,4. 1. Department of Internal Medicine, Reading Hospital, Tower Health System, West Reading, PA, USA. 2. Evidence-based Practice Center, Mayo Clinic, Rochester, MN. 3. Division of Rheumatology, Mayo Clinic, Rochester, MN. 4. Division of Rheumatology, Vanderbilt University Medical Center, Nashville, TN.
Abstract
INTRODUCTION: Psoriatic Arthritis (PsA) and Ankylosing spondylitis (AS) are chronic inflammatory diseases associated with a higher risk of cardio-metabolic comorbidities compared to the general population. Individual studies examining mortality in these patients have produced conflicting results. We performed a systematic review and meta-analysis to analyze the all-cause and cause-specific mortality in PsA and AS from the available literature. METHODS: A comprehensive database search was performed for studies reporting all-cause or cause-specific mortality in patients with PsA and AS compared with the general population. Pooled relative risks (RRs) were calculated using random-effects model. RESULTS: We included 19 studies (11 of PsA, 7 of AS, 1 of both). In PsA studies, there was no increased mortality compared to the general population (RR: 1.12, 95% CI: 0.96-1.30, 10 studies). We found a higher all-cause mortality in females (RR= 1.19, 95% CI: 1.04-1.36) but not in male (RR: 1.02, 95% CI 0.66-1.59) PsA patients. Cardiovascular, respiratory, and infection specific mortality risks were significantly higher for PsA patients (RR: 1.21, 95% CI: 1.06-1.38; RR: 3.37, 95% CI: 1.30-8.72; and 2.43, 95% CI: 1.01-5.84, respectively), but not cancer-related mortality (RR: 1.01, 95% CI: 0.91-1.11). In AS, we found a higher risk of death from all causes (RR 1.64, 95% CI: 1.49-1.80, 6 studies) and cardiovascular causes (RR 1.35, 95% CI: 1.01-1.81, 3 studies) compared to the general population. All-cause mortality was high in both males (RR 1.56, 95% CI: 1.43-1.71) and female (RR 1.85, 95% CI: 1.56-2.18) AS patients. The included AS studies did not report mortality data for non-cardiovascular causes. CONCLUSION: This systematic review and meta-analysis showed a significantly increased risk of overall mortality in AS, but not PsA. Cardiovascular-specific mortality was higher for both PsA and AS, which emphasizes the importance of early screening and management of cardiovascular risk factors. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
INTRODUCTION: Psoriatic Arthritis (PsA) and Ankylosing spondylitis (AS) are chronic inflammatory diseases associated with a higher risk of cardio-metabolic comorbidities compared to the general population. Individual studies examining mortality in these patients have produced conflicting results. We performed a systematic review and meta-analysis to analyze the all-cause and cause-specific mortality in PsA and AS from the available literature. METHODS: A comprehensive database search was performed for studies reporting all-cause or cause-specific mortality in patients with PsA and AS compared with the general population. Pooled relative risks (RRs) were calculated using random-effects model. RESULTS: We included 19 studies (11 of PsA, 7 of AS, 1 of both). In PsA studies, there was no increased mortality compared to the general population (RR: 1.12, 95% CI: 0.96-1.30, 10 studies). We found a higher all-cause mortality in females (RR= 1.19, 95% CI: 1.04-1.36) but not in male (RR: 1.02, 95% CI 0.66-1.59) PsA patients. Cardiovascular, respiratory, and infection specific mortality risks were significantly higher for PsA patients (RR: 1.21, 95% CI: 1.06-1.38; RR: 3.37, 95% CI: 1.30-8.72; and 2.43, 95% CI: 1.01-5.84, respectively), but not cancer-related mortality (RR: 1.01, 95% CI: 0.91-1.11). In AS, we found a higher risk of death from all causes (RR 1.64, 95% CI: 1.49-1.80, 6 studies) and cardiovascular causes (RR 1.35, 95% CI: 1.01-1.81, 3 studies) compared to the general population. All-cause mortality was high in both males (RR 1.56, 95% CI: 1.43-1.71) and female (RR 1.85, 95% CI: 1.56-2.18) AS patients. The included AS studies did not report mortality data for non-cardiovascular causes. CONCLUSION: This systematic review and meta-analysis showed a significantly increased risk of overall mortality in AS, but not PsA. Cardiovascular-specific mortality was higher for both PsA and AS, which emphasizes the importance of early screening and management of cardiovascular risk factors. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
Authors: Irene E van der Horst-Bruinsma; Michael T Nurmohamed; Robert B M Landewé Journal: Rheum Dis Clin North Am Date: 2012-09-14 Impact factor: 2.670
Authors: Karen M Fagerli; Lianne Kearsley-Fleet; Louise K Mercer; Kath Watson; Jon Packham; Deborah P M Symmons; Kimme L Hyrich Journal: Rheumatology (Oxford) Date: 2019-01-01 Impact factor: 7.580
Authors: Laura C Coates; Enrique R Soriano; Nadia Corp; Heidi Bertheussen; Kristina Callis Duffin; Cristiano B Campanholo; Jeffrey Chau; Lihi Eder; Daniel G Fernández-Ávila; Oliver FitzGerald; Amit Garg; Dafna D Gladman; Niti Goel; Philip S Helliwell; M Elaine Husni; Deepak R Jadon; Arnon Katz; Dhruvkumar Laheru; John Latella; Ying-Ying Leung; Christine Lindsay; Ennio Lubrano; Luis Daniel Mazzuoccolo; Philip J Mease; Denis O'Sullivan; Alexis Ogdie; Wendy Olsder; Penelope Esther Palominos; Lori Schick; Ingrid Steinkoenig; Maarten de Wit; D A van der Windt; Arthur Kavanaugh Journal: Nat Rev Rheumatol Date: 2022-06-27 Impact factor: 32.286